574
Participants
Start Date
December 31, 2005
Primary Completion Date
July 31, 2007
Study Completion Date
July 31, 2007
Lapaquistat acetate
"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
Lapaquistat acetate and additional lipid-lowering therapy
"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
Lead Sponsor
Takeda
INDUSTRY